Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price reduced by Raymond James from $16.00 to $6.00 in a report published on Tuesday, May 7th, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock.
A number of other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Adaptimmune Therapeutics from a hold rating to a buy rating and set a $5.75 price objective for the company in a report on Monday, February 4th. BidaskClub downgraded shares of Adaptimmune Therapeutics from a sell rating to a strong sell rating in a report on Tuesday, March 26th. Finally, Svb Leerink reaffirmed a market perform rating and set a $5.00 price target (down previously from $12.00) on shares of Adaptimmune Therapeutics in a report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $6.81.
ADAP stock traded up $0.06 during midday trading on Tuesday, hitting $3.46. The company’s stock had a trading volume of 267,867 shares, compared to its average volume of 309,891. The firm has a market capitalization of $338.15 million, a P/E ratio of -3.60 and a beta of 1.35. Adaptimmune Therapeutics has a twelve month low of $3.20 and a twelve month high of $14.54. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.12.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Adaptimmune Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 775,405 shares of the biotechnology company’s stock valued at $10,514,000 after buying an additional 12,113 shares during the period. SG Americas Securities LLC lifted its stake in shares of Adaptimmune Therapeutics by 157.3% in the fourth quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 12,229 shares during the period. Virtus ETF Advisers LLC lifted its stake in shares of Adaptimmune Therapeutics by 54.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 58,223 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 20,620 shares during the period. Henry James International Management Inc. bought a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at about $144,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at about $219,000. Institutional investors and hedge funds own 66.30% of the company’s stock.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: What are benefits of a growth and income fund?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.